<DOC>
	<DOC>NCT01733745</DOC>
	<brief_summary>The purpose of this study was to assess the efficacy of the SYSTANE® family of products (SYSTANE® Lid Wipes, SYSTANE® BALANCE Lubricant Eye Drops, and SYSTANE® Vitamins) on meibomian gland functionality in subjects with lipid deficiency related to evaporative dry eye as compared to the standard of care warm compresses.</brief_summary>
	<brief_title>SYSTANE® Family - Meibomian Deficiency</brief_title>
	<detailed_description />
	<mesh_term>Keratoconjunctivitis Sicca</mesh_term>
	<mesh_term>Dry Eye Syndromes</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Ophthalmic Solutions</mesh_term>
	<mesh_term>Tetrahydrozoline</mesh_term>
	<mesh_term>Lubricant Eye Drops</mesh_term>
	<criteria>Must have a clinical diagnosis of lipid deficient Evaporative Dry Eye; Meibomian Gland Functionality Not more than 6 glands yielding liquid secretion; Must be willing to discontinue the use of all other Meibomian Gland; Dysfunction management prior to receiving the study test article at Visit 1, up until the end of the study period; Must have best corrected visual acuity of 20/40 Snellen or better in each eye; Must be able to follow instructions and be willing and able to attend required study visits; Must read, sign, and date an Ethics Committee reviewed and approved informed consent form; Other protocoldefined inclusion criteria may apply. History or evidence of ocular or intraocular surgery or serious ocular trauma in either eye within the past 6 months; Current punctal occlusion of any type (e.g., collagen plugs, silicone plugs); History of intolerance or hypersensitivity to any component of the study medications; History or evidence of epithelial herpes simplex keratitis (dendritic keratitis); vaccinia; active or recent varicella viral disease of the cornea and/or conjunctiva; chronic bacterial disease of the cornea and/or conjunctiva and/or eyelids; mycobacterial infection of the eye; and/or fungal disease of the eye; Pregnant or lactating at the time of enrollment; Not willing to take adequate precautions not to become pregnant during the study; Use of any concomitant topical ocular medications during the study period; Use of systemic medications that may contribute to dry eye unless on a stable dosing regimen for a minimum of 30 days prior to Visit 1; Ocular conditions that may preclude the safe administration of either drop under investigation; Unwilling to discontinue contact lens wear during the study period and for at least 1 week prior to Visit 1; Participation in an investigational drug or device study within 30 days of entering this study; Other protocoldefined exclusion criteria may apply.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2014</verification_date>
	<keyword>dry eye</keyword>
	<keyword>lipid deficiency</keyword>
	<keyword>meibomian gland</keyword>
</DOC>